Appropriateness of Combination Therapy for Patients With Inflammatory Bowel Diseases: One Size Still Does Not Fit All
- 1 November 2018
- journal article
- letter
- Published by Elsevier in Clinical Gastroenterology and Hepatology
- Vol. 16 (11) , 1829-1831
Abstract
No abstract availableKeywords
This publication has 10 references indexed in Scilit:
- Association Between Use of Thiopurines or Tumor Necrosis Factor Antagonists Alone or in Combination and Risk of Lymphoma in Patients With Inflammatory Bowel DiseaseJAMA, 2017
- Risk for Overall Infection with Anti-TNF and Anti-integrin Agents Used in IBDInflammatory Bowel Diseases, 2017
- Effects of Concomitant Immunomodulator Therapy on Efficacy and Safety of Anti–Tumor Necrosis Factor Therapy for Crohn’s Disease: A Meta-analysis of Placebo-controlled TrialsClinical Gastroenterology and Hepatology, 2015
- Comparative Effectiveness of Immunosuppressants and Biologics for Inducing and Maintaining Remission in Crohn's Disease: A Network Meta-analysisGastroenterology, 2015
- Adalimumab monotherapy versus combination therapy with immunomodulators in patients with Crohn's disease: A systematic review and meta-analysisJournal of Crohn's and Colitis, 2014
- Methotrexate in Combination With Infliximab Is No More Effective Than Infliximab Alone in Patients With Crohn's DiseaseGastroenterology, 2014
- Combination Therapy With Infliximab and Azathioprine Is Superior to Monotherapy With Either Agent in Ulcerative ColitisGastroenterology, 2014
- The Appropriateness of Concomitant Immunomodulators With Anti–Tumor Necrosis Factor Agents for Crohn's Disease: One Size Does Not Fit AllClinical Gastroenterology and Hepatology, 2010
- Infliximab, Azathioprine, or Combination Therapy for Crohn's DiseaseNew England Journal of Medicine, 2010
- Clinical trial: benefits and risks of immunomodulators and maintenance infliximab for IBD‐subgroup analyses across four randomized trialsAlimentary Pharmacology & Therapeutics, 2009